HBME-1 expression in differentiating benign and malignant thyroid lesions
Thyroid carcinomas are classically diagnosed based on specific morphological criteria. In some cases, a definitive diagnosis may be difficult when morphological features are equivocal. This study evaluated the utility of Hector Battifora Mesothelial-1 (HBME-1) as an immunohistochemical marker to dif...
Main Authors: | Noor 'Ain MN (Author), Nordashima Abd Shukor (Author), Mohd Rohaizat Hassan (Author), Mazne M (Author), Azyani Yahaya (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Pusat Perubatan Universiti Kebangsaan Malaysia,
2020.
|
Online Access: | Get fulltext |
Similar Items
-
"MONOCLONAL ANTIBODY HBME-1 USEFULNESS IN DIFFERENTIATION OF BENIGN NEOPLASM AND DIFFERENTIATED THYROID CARCINOMA"
by: M. Mokhtari, et al.
Published: (2005-04-01) -
"MONOCLONAL ANTIBODY HBME-1 USEFULNESS IN DIFFERENTIATION OF BENIGN NEOPLASM AND DIFFERENTIATED THYROID CARCINOMA"
by: M. Mokhtari, et al.
Published: (2005-05-01) -
CD56, CD57, HBME1, CK19, Galectin-3 and p63 immunohistochemical stains in differentiating diagnosis of thyroid benign/malign lesions and NIFTP
by: Ebru Tastekin, et al.
Published: (2020-03-01) -
CD56, HBME-1 and cytokeratin 19 expressions in papillary thyroid carcinoma and nodular thyroid lesions
by: Senay Erdogan-Durmus, et al.
Published: (2016-01-01) -
Expression of ck-19, galectin-3 and hbme-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis
by: de Matos Leandro, et al.
Published: (2012-08-01)